PEG-PCL from PolySciTech used in development of nerve regeneration therapy for paralysis treatment.

 

After nerve injury, due to disease or trauma, skeletal muscles undergo denervation atrophy which prevents the possibility for recovery from paralysis. There is no treatment for this atrophy currently. Researchers at  Johns Hopkins University used mPEG-PCL (AK128, https://akinainc.com/polyscitech/products/polyvivo/index.php?highlight=AK128#h) from PolySciTech : Akina, Inc. (www.PolySciTech.com) to develop a nanofiber hydrogel composite which delivers myoblast cells along with growth factors to encourage nerve tissue regeneration. This was tested in rat model and showed promise to restore strength and mobility. This research holds promise to provide for treatment of nerve-tissue damage based paralysis. Read more: Dias, Shaquielle, William Padovano, Chenhu Qiu, Thomas Harris, Rachana Suresh, Erica Lee, Eszter Mihaly et al. "Myoblast Therapy Ameliorates Skeletal Muscle Atrophy Resulting From Chronic Denervation." Muscle & Nerve (2026). https://onlinelibrary.wiley.com/doi/abs/10.1002/mus.70254

“Skeletal muscle undergoes progressive denervation-induced muscle atrophy (DIMA) after peripheral nerve injury that severely impairs the potential for motor functional recovery with reinnervation. There are currently no therapeutic strategies to reverse the deleterious effects of chronic DIMA, leaving affected patients with lifelong disability. Herein, we used a translational rodent forelimb nerve injury model to investigate whether targeted injection of syngeneic myoblasts to chronically atrophic muscle can reverse the histologic and functional consequences of DIMA. Male Lewis rats underwent median nerve transection followed by immediate (positive control) or delayed repair. Following a plateau of motor function, myoblasts were injected into the digital flexor muscles (n = 5–6 per group), delivered in either saline or a nanofiber hydrogel composite (NHC) loaded with agrin- and insulin-like growth factor 1 (IGF-1)-releasing nanoparticles (npNHC). Serial functional assessments of stimulated grip strength and terminal histological evaluation were used to measure recovery. Satellite cell-rich (Pax7Hi) myoblast therapy caused sustained improvement in stimulated grip strength from pretreatment baseline (p < 0.05). Histological evaluation demonstrated that myoblast therapy, when delivered in npNHC, reversed whole muscle atrophy compared to positive controls [p = 0.997 and 0.996] and restored mean myofiber cross-sectional area [p = 0.244]. Correlation analysis demonstrated functional improvements were associated with increased myofiber cross-sectional area [r = 0.900, p = 3.01E-09]. This data indicates that targeted injection of syngeneic myoblasts can reverse the functional and histologic effects of DIMA in skeletal muscles and is a promising strategy for improving recovery after peripheral nerve injuries.”

Benchtop to Bedside with MidWestGMP https://www.akinainc.com/midwestgmp/

Corbion Purasorb® Polymers: https://akinainc.com/polyscitech/products/purasorb/

Ashland-TM Polymer Products: https://akinainc.com/polyscitech/products/ashland/

PrecisionGelTM from Vivos https://akinainc.com/polyscitech/products/vivos/